Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 3/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17296021 | 1.00 | HRH4 (0.45) | HRH4HRH3ROCK2ROCK1CDC42BPB | |
| SCHEMBL18239409 | 0.75 | KDM4E (0.49) | HRH4HRH3ROCK2ROCK1CDC42BPB | |
| SCHEMBL18890299 | 0.74 | HRH4 (0.47) | HRH4HRH3PTPN11GLSAKT1 | |
| SCHEMBL29544097 | 0.74 | HRH4 (0.47) | HRH4HRH3PTPN11GLSAKT1 | |
| SCHEMBL15378778 | 0.73 | DPP4 (0.47) | HRH4HRH3GLS | |
| SCHEMBL17309195 | 0.73 | DPP4 (0.47) | HRH4HRH3GLS | |
| Hydrochloric Acid SCHEMBL18228248 | 0.73 | KDM4E (0.48) | HRH4HRH3ROCK2ROCK1CDC42BPB | |
| SCHEMBL15378779 | 0.73 | DPP4 (0.47) | HRH4HRH3GLS | |
| Hydrochloric Acid SCHEMBL17295980 | 0.72 | DPP4 (0.46) | HRH4HRH3GLS | |
| Hydrochloric Acid SCHEMBL18890084 | 0.72 | DPP4 (0.46) | HRH4HRH3GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294221-B2 | 1, 3, 4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-05-21 | — | — | US | disclosed |
| US-10294221-B2 | 1, 3, 4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-05-21 | — | — | US | disclosed |
| US-20180305349-A1 | 1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-10-25 | — | — | US | disclosed |
| US-10040788-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| US-10040788-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| US-10040788-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| EP-3148994-B1 | 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-07-11 | — | — | EP | disclosed |
| EP-3148994-B1 | 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-07-11 | — | — | EP | disclosed |
| US-20170197954-A1 | 1,3,4-Thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197954-A1 | 1,3,4-Thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197954-A1 | 1,3,4-Thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2017-07-13 | — | — | US | disclosed |
| WO-2015181539-A1 | 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305349-A1 | 1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer | GLS2, GLS, GSS | HRH4 1466/4885HRH3 1980/4885ROCK2 1715/4885 |
| US-10294221-B2 | 1, 3, 4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GSS | HRH4 1466/4885HRH3 1980/4885ROCK2 1715/4885 |
| US-20170197954-A1 | 1,3,4-Thiadiazole compounds and their use in treating cancer | GLS2, GLS, GSS | HRH4 1438/4885HRH3 1949/4885ROCK2 1703/4885 |
| US-10040788-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GSS | HRH4 1438/4885HRH3 1949/4885ROCK2 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.